Winter, 2015



5 Stocks Set to DOUBLE

ZACKS | Our Research. Your Success.

Contents

Overview

Thank you for your interest in Zacks and the 5 Stocks Set to Double report. This report will give you an idea of the enormous resources available on Zacks.com. I invite you to visit the site and get familiar with the Zacks Rank, our stock picking framework that has an impressive track record of generating market-beating returns year after year.

Each of the 5 stocks in this report was hand-picked by one of our stock strategists, who explain their rationale in the included stock write-ups. Clearly, this report was not written for the risk-adverse or conservative investor. Rather, these stocks are for the aggressive investor looking to add home-run potential to his or her portfolio. It would be prudent to devote no more than a small portion of your overall portfolio to these stocks.

That said, we hardly threw darts at a board to arrive at these choices. All of the stocks have catalysts that we think could fuel strong gains over the coming year. We sifted through stocks that met Zacks Rank criteria and then chose the crème de la crème. Each of the five stocks has unique qualities that make it a candidate for this report. And they are all from different sectors, offering a level of diversification even in this small sample.

Most of the stocks in this report are currently flying under the radar of most Wall Street analysts and traders, which provides a good opportunity to get in on the ground floor. The market is littered with these kinds of stocks, but only the ones with positive catalysts on the horizon burst onto the scene with monstrous gains. We made sure that we could identify specific factors that would bring these stocks out from obscurity and onto the lists of top performing stocks.

We are confident that you can realize enormous gains with these 5 stocks. Leave the singles and doubles for other portfolios; we are swinging for the fences on this one!

Best regards,

Sheraz Mian

Celldex Therapeutics (CLDX)

When searching for a stock with the potential to double in a relatively short time (12-18 months), I am often drawn to the world of Biotechnology companies.

In December of 2014, I chose Seattle Genetics (SGEN) around $35 for my "doubler" and it went over $50 by this past summer for a possible gain of over 40% in about six months.

But to remind us that there is always extra risk with Biotech stocks, my June 2015 pick went the other way. I recommended Sangamo BioSciences (SGMO) between $12 and $13, but the company ran into some obstacles in their R&D pipeline and the stock fell to $6 before recovering back to $9 this month.

Part of my criteria for choosing both of these companies was that their shares were still being accumulated by one of my favorite institutional Biotech investors, the Baker Brothers funds, run by Julian and Felix Baker with Tisch family money. Julian is the businessman and Felix is the life sciences Ph.D.

The Baker boys aren't in today's pick, but many high-profile mutual fund companies and aggressive growth stock pickers are. Since I track the buying of these institutional investors every day for my Zacks Follow the Money (FTM) trading service, at the end of this report I'll share with you the big recent buyers.

With this risk/reward backdrop for Biotech companies understood, let's take a look at this December's pick...

Celldex Therapeutics (CLDX) is a $1.6 billion biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. The company has a brain tumor drug, Rintega, in Phase 2 FDA clinical trials and recent data from the study was well-received by the medical community at the November meeting of the Society for Neuro-Oncology.

More on Rintega in a moment. First I want to give the big picture on this company's R&D platform. Immunotherapy is an exciting new field in the life sciences that could offer many breakthrough cures for cancer eventually. Here's how the American Society of Clinical Oncology (ASCO) describes this cutting edge science...

Immunotherapy, also called biologic therapy, is a type of cancer treatment designed to boost the body's natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function. It is not entirely clear how immunotherapy treats cancer. However, it may work in the following ways:

- Stopping or slowing the growth of cancer cells
- Stopping cancer from spreading to other parts of the body
- Helping the immune system work better at destroying cancer cells.

There are several types of immunotherapy, including monoclonal antibodies, non-specific immunotherapies, and cancer vaccines.

Getting to Know Celldex

Celldex is currently a Zacks #2 Rank because analysts were recently motivated by the company's R&D and financial progress to raise estimates across the board. The company is still projected to post a loss of $1.38 next year, but it looks like some of the pieces are beginning to turn around.

Here's how the company describes their business...

Celldex was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases.

The company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications.

This has created a leading pipeline in immunotherapy comprised of two candidates in pivotal trials, one in brain cancer and one in triple negative breast cancer, four additional clinical candidates in a range of difficult-to-treat indications and a robust preclinical engine.

Getting Through the FDA Gauntlet

CLDX shares took a beating this year, dropping from a 52-week high over $32 to a 52-week low of $10 from March to September. In August, the selling really kicked in after the company revealed that the FDA wants to see the Phase 3 trial results before they consider Rintega for a new drug application.

In the drug approval process, the holy grail for Biotech companies and their investors is solid and promising data that earns a given drug "fast track" approval designation even before Phase 3 trials.

This early "fast track" designation was hoped for because Rintega is designed to target an especially vicious type of brain tumor called a glioblastoma that multiplies cancer cells quickly and can lead to death within 2 to 3 years. The FDA tends to favor new R&D that serves a currently unmet need or small population. Here's how the American Brain Tumor Association describes this brain tumor which can be found between the hemispheres and near the spinal cord...

Glioblastomas (GBM) are tumors that arise from astrocytes—the star-shaped cells that make up the "glue-like," or supportive tissue of the brain. These tumors are usually highly malignant (cancerous) because the cells reproduce quickly and they are supported by a large network of blood vessels.

Better News in November Moves Stock from $12 to $18

But things started looking brighter for Rintega recently after the company previewed some good news on their early November conference call ahead of the Society for Neuro-Oncology Conference in San Antonio.

At the conference, Celldex made presentations with positive long-term survival data from the Phase 2 studies and touted what it called the "consistent, impressive story" of its brain cancer vaccine. According to Eric Saganowsky writing for the industry newsletter FierceBiotech...

In a 73-patient Phase II trial of glioblastoma patients with the EGFRvIII mutation, 25% of those who received Rintega plus Roche's Avastin were alive after two years, while no patients who received only Avastin were alive. Rintega's advantages were further shown over endpoints such as overall survival, progression-free survival, objective response rate and need for steroids, Celldex added.

Analysts were very encouraged by these results and they look forward to Phase 3 results of another study involving Rintega which is due to complete in November of 2016. Oppenheimer analysts believe the Rintega market opportunity is underappreciated and could yield at least $400 million in peak sales. They said "Rintega's nontoxic safety profile and the high unmet medical need in GBM could lead to a very quick launch." The firm reiterated their Outperform rating and 12-18 month price target of $42.

And Roth Capital Partners believes Celldex is solidifying its position as a premier cancer immunotherapy company with a broad pipeline and partnering potential. They maintained CLDX shares as a Focus Pick with a $39 price target.

That last point from Roth analysts about "partnering potential" is important. In the world of small Biotech companies with developmental-stage drugs, a "big brother" from established Pharma is often needed to help fund the long and expensive road of R&D toward the FDA gauntlet. Besides the extra capital and R&D support, teaming up with a bigger Biopharma company adds a big dose of legitimacy to the smaller company's science.

I don't believe Celldex has such a partner yet to invest and share in their potential success. So the door is open for that upside surprise.

To track the company's news releases and pipeline progress, here is a link to their website pipeline page.

Whales Who Like CLDX

As I told you, I track institutional buyers in Zacks #1 Rank and #2 Rank stocks. These "whales" of the market can make the difference in many investments. Here's a look at the top holders who were all buyers in the third quarter of 2015, which means some probably got caught holding shares they picked up in July around $25, while others were lucky be scooping better bargains under $14 in September. *Data table courtesy of Nasdaq.com…*

88 Increased Institutional Holders
9,900,632 Increased Total Shares Held

Click on the column header links to resort ascending (▲) or descending (▼).

Owner Name	Date	Shared Held	Change (Shares)	Change (%)	Value (in 1,000s)
OPPENHEIMER FUNDS INC	09/30/2015	9,176,578	381,752	4.34	162,609
FRANKLIN RESOURCES INC	09/30/2015	9,078,447	439,362	5.09	160,870
VANGUARD GROUP INC	09/30/2015	6,572,533	213,787	3.36	116,465
FIRST TRUST ADVISORS LP	09/30/2015	4,809,887	467,502	10.77	85,231
BLACKROCK FUND ADVISORS	09/30/2015	3,761,916	122,103	3.36	66,661
FRONTIER CAPITAL MANAGEMENT CO LLC	09/30/2015	3,498,712	1,002,880	40.18	61,997
STATE STREET CORP	09/30/2015	3,191,036	597,583	23.04	56,545
COLUMBIA WANGER ASSET MANAGEMENT LLC	09/30/2015	3,109,615	517,912	19.98	55,102
REDMILE GROUP, LLC	09/30/2015	1,954,019	1,921,254	5,863.74	34,625
DEUTSCHE BANK AG\	09/30/2015	1,421,786	85,293	6.38	25,194
UBS GLOBAL ASSET MANAGEMENT AMERICAS INC	09/30/2015	1,223,015	54,958	4.71	21,672
NORTHERN TRUST CORP	09/30/2015	1,086,042	9,369	.87	19,245
SUSQUEHANNA INTERNATIONAL GROUP, LLP	09/30/2015	891,358	405,465	83.45	15,795
TSP CAPITAL MANAGEMENT GROUP, LLC	09/30/2015	824,681	12,000	1.48	14,613
MILLENNIUM MANAGEMENT LLC	09/30/2015	764,343	210,870	38.10	13,544

Oppenheimer and Franklin are the second and third largest shareholders. The largest holder is not present on this list because while Fidelity still holds nearly 14.5 million shares, they actually sold about 300k in Q3. To me, this is a stellar list of institutional support in this name with all the big guns still adding shares. I recommend accumulating CLDX shares between $14 and $18.

Cross Country (CCRN)

My stock to double is at the center of the intersection of two great industries. While there may have been some hiccups in healthcare, there's no question that it will continue to be a growing business over the next year. And in growing that business, there will plenty of employment opportunities popping up. What better way to take advantage of that than a healthcare staffing business? That's right, my stock is the love child of healthcare and staffing. Two industries that should remain red-hot over the course of the next year.

Top Stock, Top Industry

The staffing industry ranks in the Top 5% of our Zacks Industry Rank and today's stock to double is a Zacks Rank #1 (Strong Buy) in that industry. In addition to the Zacks Rank, the stock is rocking Growth and Momentum Style Scores of "A."

Cross Country (CCRN) provides healthcare staffing and workforce solutions in the United States. The company operates through three segments: Nurse and Allied Staffing, Physician Staffing, and Other Human Capital Management Services.

CCRN is coming off a blowout Q3 with higher revenues, higher than expected price increases and earlier than expected cost savings the increased margins 180 bps above expectations. Revenues came in at $195.7 million versus street expectations of $193.8 million. EPS came in at 23 cents versus our Zacks Consensus Estimate at 11 cents.

Accretive Acquisitions

The company believes that they can continue to grow market share. While they are currently the second largest by market share in the industry, that share is still only 7%. Management thinks that one way to grow is through acquisitions, like the recent Mediscan deal. Mediscan looks to be accretive this quarter and should add 6 to 7 cents to 2016 EPS.



The bullish sentiment has analysts upping their earnings estimates across the board. The most dramatic increases can be seen in the current year and next year numbers. The Zacks Consensus Estimate for the current year has shot up from 34 cents to 53 cents over the last 60 days, while its jumped from 46 cents to 67 cents for next year. With four analysts raising their estimates for both periods, it's no wonder why this stock is a Zacks Rank #1 (Strong Buy).

A quick look at the Price and Consensus chart shows how the stock has turned around along with earnings estimates. The stock struggled throughout 2011 and 2012 as estimates steadily dropped. It wasn't until a turnaround in mid-2014 that things really started to pick up for shares of CCRN. With shares trading under $7, the growth prospects returned. Along with them, estimates started to creep up slowly and the stock began to rocket higher. Those estimates began to stall a bit in 2015 until recently. Now it looks like the stock is primed for the next leg higher.



You can see just how bullish the revisions have made Wall Street. Shares bounced off $10 in early June, pushing all the way to a new 52-week high in September at $16.72. Some extreme volatility took shares all way down from $16 to under $11.50 in two short days in October during the downturn. That proved to be one of the best buying opportunities of the year. CCRN found buyers down in the low teens and turned around to make new highs less than two weeks later.

It seems like shares are still riding that wave of momentum. A slight increase in volume has confirmed renewed institutional interest in the stock. Currently shares are trading less than a dollar off the fresh 52-week high. Support looks to be solid where a thick band of volume was traded at $16. To the upside, resistance is likely at $20. This gives you a very comfortable risk versus reward scenario with shares at $17.78.

ServiceSource (SREV)

Turnaround stories are potential opportunities to find a company with a good idea, yet was bad at implementing the business. But, to know when management has begun to turn the ship in the correct direction, before the stock price jumps up, is the key to achieving big gains for the investor. This is the situation with ServiceSource International Inc. (SREV).

ServiceSource is currently in a turnaround phase, and we have seen strong indications that the ship is now moving in the right direction. So much so, that the company is now expecting double-digit growth in 2017.

This Zacks Rank #1 (Strong Buy) provides a suite of cloud applications for service revenue management. The Company provides end-to-end management and optimization of the service contract renewals process, including data management, quoting, selling, and service revenue business intelligence. Its solution is based on the proprietary Service Revenue Intelligence Platform, a data warehouse that incorporates transactional, analytical and industry data gathered from over two million service renewal transactions. The Company's offering finds its application in all industries.

This San Francisco based company was founded in 1999, and has an impressive list of customers; Adobe, Microsoft, VMware, NetApp, Siemens, Salesforce, Roche, and Rockwell Automation. Further the company was awarded the 2015 Bronze Stevie Award in The 13th Annual American Business Awards, which is considered the nation's premier business awards program, in the New Product or Services of the Year – Software – Relationship Management Solution category.

Positive Traction

In their most recent earnings announcement, ServiceSource saw Cloud and Business Intelligence revenue improve, while margins surged in the Managed Services division. This was the first time since Q3 14 that Cloud and Business Intelligence segment reported positive growth. Further, due to the better than expected performance in the Managed Services division, overall gross margins were 32.4%, much higher than initially expected. The improvement in the Cloud and Business Intelligence is seen as the big indicator that management's turnaround strategy is working.

Looking forward, the company announced their expansion into the Philippines, which is expected to open in Q1 16. The office will increase capacity for the company and will be used to deliver back office services. Further, management expects the office to open up their revenue lifecycle management (RLM) business to new opportunities in the region.

Also, management has stated that they have a strong pipeline of new deals for the fourth quarter 2015, and into 2016 as well. In the third quarter, management signed 12 deals, and increased their average contract dollars for the third consecutive quarter. This momentum is expected to produce double-digit growth in 2017, and/or 2018 according to management.

According to Christopher Carrington, CEO, "The team at ServiceSource delivered another solid quarter as we continue strong progress on our turnaround. With revenue near the high-end of guidance and continued cost management, we exceeded our expectations on profitability and improved our adjusted EBITDA by $6 million year-over-year. Our client-facing teams continued their great work tightening relationships with current clients, growing deal sizes, and expanding the pipeline. Additionally, we announced our plans to open a service center in the Philippines, an important move to meet increasing demand for RLM and our future growth. With a new executive management team driving a revitalized culture, I remain confident our team will continue to make the operational improvements necessary to return ServiceSource to growth and profitability."

Increasing Estimates

ServiceSource has met or beaten the Zacks Consensus Earnings and Revenue estimates for the past 5 consecutive quarters. On the earnings side, the company has produced a four quarter average positive earnings surprise of +53.5%. Further, due to the company's most recent earnings announcement, the Zacks Consensus Earnings estimates for Q4 15, Q1 16, FY 15, and FY 16 have all risen over the past 30 days.

As you can see from the graph below, the 2016 estimates for ServiceSource, are more than double their current price.



In the second graph you can see that ServiceSource has been outperforming the S&P 500 for the last six months as well.



Bottom Line

Currently, the stock price is relatively very cheap, and is expected to significantly improve by the end of 2016. As management continues their turnaround process, most every indication is showing that the company is now well positioned to achieve double-digit growth by 2017. With expanding margins, improved Cloud and Business Intelligence revenues, and a Managed Services division that is significantly ahead of forecasts, expectations are now starting to rise.

TAL Education Group (XRS)

TAL Education Group (XRS) is a leading K-12 after-school tutoring services provider in China. The acronym "TAL" stands for "Tomorrow Advancing Life," which according to the company, reflects their vision to promote top learning opportunities for K-12 students through high-quality teaching and content, as well as leading edge application of technology in the education experience.

They have learning centers in 19 major cities in China and also operate an online education platform. They offer tutoring services in many subjects and in multiple formats including small class, one-on-one and online courses.

The company IPO'd in 2010 and has seen exponential growth since then, with 571% growth in student enrollments and 163% growth in number of learning centers.

Excellent Quarterly Results and Strong Guidance

The company reported its Q2 FY 2016 results on October 22. Net revenue increased 41.6% year-over-year to $173.3 million, driven primarily by a 55% jump in enrollments. Operating income increased 28.5% year-on-year.

Net income of $0.72 per share (ADS) was way ahead of the Zacks Consensus Estimate of $0.38. The company has delivered a beat in three out of last four quarters, with an average positive quarterly surprise of 23%.

Thanks to strong performance in the first-half, the management now expects net revenue for fiscal year 2016 to grow 40% to 42% in RMB terms, as compared to the 35% revenue growth posted last year.

Rising Estimates

After strong results, analysts have increased their estimates for the company. Zacks Consensus Estimates for the current and the next fiscal year are now $1.37 per share and $1.49 per share respectively, up from $1.01 and $1.40, before the results.

Chinese Consumer Remains Strong

China's economy grew 6.9% in the third quarter-- its weakest level since 2009—but stronger than the consensus forecast of 6.8%. Some believe that the growth trend reflects a steady rebalancing of the world's second largest economy's growth model from manufacturing and investments to services and consumption led growth.

Services, which now account for more than 50% of the output, grew 8.6% year-over-year, as Chinese consumers are spending more with rising incomes and still healthy labor market. Chinese e-commerce giant Alibaba reported an eye-popping $14.3 billion in sales during their online shopping event, "Singles' Day" last month. Sales were up 54% from last year's event.

As the middle class and their incomes continue to grow, consumer spending is going to surge going forward. Per Economist, mainstream consumers in China (those with enough money to buy cars, fridges and phones) made up less than a tenth of urban households in 2010; by 2020 they are expected to make up over 50%. Private consumption will rise from $3.2 trillion today to $5.6 trillion in 2020.

In fact, some believe that increasing consumer spending can at least partly offset the slowdown in manufacturing and investments. Moreover, the private education industry in China is expected to continue to grow exponentially despite broader economic slowdown, as explained below.

China’s Booming Private Education Industry

China has an extremely competitive education system. Children have to take entrance exams right from the kindergarten level for admissions into primary schools, middle schools, high schools and colleges. Chinese parents are usually more than willing to spend large sums on tutoring which can prepare their kids for these entrance exams. They want their kids to secure the best possible education that they hope will lead to a better life.

Due to one child policy (which ended just a few weeks back), parents often make enormous sacrifices to ensure that their child goes much farther than they could have hoped for themselves and then also take care of them in their old age.





The Bottom Line

The company has a recognized brand name and a leadership position in a large, attractive and growing market. Private education industry in China has been growing rapidly thanks mainly to rising incomes of the expanding middle class in the country. The industry still has a lot of untapped expansion potential.

The company’s growth strategy focuses on further penetrating existing markets by opening new learning centers as well as entering new markets. In addition to a top Zacks Rank, the stock has a Momentum Style Score of “A” and Growth Style Score of “B”. The stock has been a solid performer of late and given the company’s excellent growth potential, I believe that the stock will maintain its uptrend in the coming months.

Qualys (QLYS)

The threat from cyber security is rising.

Each year we read about new attacks on major blue chip companies ranging from Sony to Target, while even the United States government (among other national governments around the globe) recognizes the threat from cyber terrorism and the potential for cyber disruptions to impact markets all over the world.

This is increasing the importance of cyber security companies which can help to mitigate the risks from these devastating cyber events and investors are definitely putting extra attention on the space as a result. In fact, an ETF was recently launched to track the space, HACK, and it has surged to one billion dollars under management in just seven months, further underscoring the investor interest in this corner of the market.

Which companies to pick?

If an ETF approach isn't your thing in the cyber security market, you are in luck. There are several stocks that are well-positioned for huge gains and could be excellent additions in this cyber-focused market. One that should definitely be on your short list is Qualys (QLYS).

Qualys is a California-based company that specializes in a variety of security services including PCI compliance, web app scanning, and malware detection. In addition, the company has a cloud-focused program which helps to identify and fix vulnerabilities, as well as analyze IT security data.

The company isn't a giant overall cyber market, but it has great potential thanks to its focus on the cloud. The market of cloud computing is surging, and as more products and services go onto the cloud, securing this for all types of companies will become a vital task that cannot be overstated. Look at some of the companies that already are using QLYS services:

Overall, QLYS is just a well-positioned small cap stock that is focused on some markets with great growth potential. And if you look to some of the company's fundamentals, there is plenty to like about this stock.

QLYS Fundamentals & Earnings

Thanks in part to the solid position for QLYS in the industry and its longer term potential, analysts have been boosting their estimates for Qualys stock. In fact, at time of writing, not a single estimate by analysts tracking the company was revised lower for either the current quarter, next quarter, current year, or next year time frames.

Current EPS growth rates are also impressive for QLYS as the company looks to see 35% growth this year and then 18.5% growth in 2016. And with sales growth expected to be well above the industry average, coming in at 23.3% compared to 14.8% for the industry, and with current cash flow growth expected to double, this is looking to be an impressive security.

This could be especially true if investors dial into the recent earnings estimate revisions and the impact they have had on the consensus estimate for QLYS stock. For the current quarter, the EPS consensus has tripled in just the past few months, while we have also seen strong gains for the current year and next year time frames too. In fact, these current year and next year consensus estimates have been revised upward by, respectively, 54% and 26% in just the past few months.

The true importance of this can be seen if we look at the year ago EPS for QLYS which was 27 cents per share. Roughly a quarter ago, the current year EPS estimate was just 24 cents per share, a figure that would give QLYS an earnings contraction for the time frame.

Now though, with the EPS estimate going up to 37 cents a share, the company is expected to see strong growth. In other words, opinion on QLYS has drastically improved as of late and expectations are now riding much higher on the near term prospects for the company.

But before you start to worry over QLYS living up to the hype, consider its recent history in earnings season. The stock hasn't missed earnings since February 2014 and it has crushed earnings estimates in each of the last four quarters suggesting it knows how to deliver in earnings season.

Surprise - Reported Earnings History [?]

	Quarter Ending (9/2015)	Quarter Ending (6/2015)	Quarter Ending (3/2015)	Quarter Ending (12/2014)	Average Surprise
Reported	0.07	0.09	0.08	0.09	NA
Estimate	0.05	0.03	0.06	0.02	NA
Difference	0.02	0.06	0.02	0.07	0.04
Surprise	40.00%	200.00%	33.33%	350.00%	155.83%

Yet, even with these beats and strong growth prospects in the industry, shares of QLYS have sold off a bit lately. Though shares seem to have bottomed for now, they still have plenty of room to run before they can get back to 2015 highs making it a potentially great time to consider QLYS stock for your portfolio as the market has not recognized the potential in this small cap security.

Bottom Line

Cyber security is an important area of the market and it isn't like these cyber attacks are going away anytime soon. That is why it is probably a good idea to have at least some exposure to securities in this area of the economy, and QLYS definitely stands out in this regard.

Not only is QLYS in a key area of the market—cloud security—but it has great fundamentals and analyst support as well. Plus, considering its recent pullback, shares are trading at much better valuations now, making it a very intriguing choice. So if you are looking for a pick that has the potential to double in the cyber security industry, definitely give Qualys (QLYS) a closer look for your portfolio.

What to Do Next

In addition to the hand-selected picks included in this special report, you can move yourself way ahead of the crowd in any market environment with the following:

- As part of this free report, you will now receive our free daily e-newsletter, Profit from the Pros. Each morning, Executive Vice President Steve Reitmeister will summarize the market, what it means for investors and what to do next. Plus you get links to articles featuring some of our top stock, ETF and mutual fund recommendations. Be sure to look for it in your email inbox before the markets open every day.

- Now you should bookmark our homepage to take advantage of one of the most complete investment websites around. Go there now:

  www.zacks.com

- Even better, get all Zacks' private buys and sells through our Zacks Ultimate program. Watch our trades and market insights from all of Zacks' private portfolios from growth to value to momentum stocks, from insider moves to big earnings surprises, from options to ETFs, even trades EVP Steve Reitmeister makes in his personal account, and much more. This see-everything arrangement is unique: one month, one dollar, not one cent of further obligation.

  Learn more about the Zacks Ultimate Trial now